137 related articles for article (PubMed ID: 9825479)
1. The relevance of somatostatin receptors in thyroid neoplasia.
Ahlman H; Tisell LE; Wängberg B; Fjälling M; Forssell-Aronsson E; Kölby L; Nilsson O
Yale J Biol Med; 1997; 70(5-6):523-33. PubMed ID: 9825479
[TBL] [Abstract][Full Text] [Related]
2. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
3. Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid.
Tisell LE; Ahlman H; Wängberg B; Kölby L; Fjälling M; Forssell-Aronsson E; Mölne J; Nilsson O
Br J Cancer; 1999 Mar; 79(9-10):1579-82. PubMed ID: 10188909
[TBL] [Abstract][Full Text] [Related]
4. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
[TBL] [Abstract][Full Text] [Related]
5. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor subtypes, octreotide scintigraphy, and clinical response to octreotide treatment in patients with neuroendocrine tumors.
Kölby L; Wängberg B; Ahlman H; Tisell LE; Fjälling M; Forssell-Aronsson E; Nilsson O
World J Surg; 1998 Jul; 22(7):679-83. PubMed ID: 9606281
[TBL] [Abstract][Full Text] [Related]
7. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
[TBL] [Abstract][Full Text] [Related]
8. [Somatostatin receptor status in non-medullary thyroid carcinoma].
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
[TBL] [Abstract][Full Text] [Related]
9. Scintigraphy with [111In]octreotide and 201Tl in a Hürthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature.
Kostoglou-Athanassiou I; Pappas A; Gogou L; Kaldrymides P
Horm Res; 2003; 60(4):205-8. PubMed ID: 14530610
[TBL] [Abstract][Full Text] [Related]
10. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
[TBL] [Abstract][Full Text] [Related]
11. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy in medullary thyroid carcinoma.
Tisell LE; Ahlman H; Wängberg B; Hansson G; Mölne J; Nilsson O; Lindstedt G; Fjälling M; Forssell-Aronsson E
Br J Surg; 1997 Apr; 84(4):543-7. PubMed ID: 9112914
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
14. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor expression in Hürthle cell cancer of the thyroid.
Gulec SA; Serafini AN; Sridhar KS; Peker KR; Gupta A; Goodwin WJ; Sfakianakis GN; Moffat FL
J Nucl Med; 1998 Feb; 39(2):243-5. PubMed ID: 9476928
[TBL] [Abstract][Full Text] [Related]
16. Cerebellar metastasis of papillary thyroid carcinoma detected with somatostatin receptor scintigraphy.
Czepczyński R; Wyszomirska A; Gryczyńska M; Szczepanek-Parulska E; Ruchała M
Endokrynol Pol; 2018; 69(1):24-27. PubMed ID: 29319129
[TBL] [Abstract][Full Text] [Related]
17. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
[TBL] [Abstract][Full Text] [Related]
18. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor scintigraphy in non-medullary thyroid cancer.
Postema PT; De Herder WW; Reubi JC; Oei HY; Kwekkeboom DJ; Bruining HJ; Bonjer J; van Toor H; Hennemann G; Krenning EP
Digestion; 1996; 57 Suppl 1():36-7. PubMed ID: 8813465
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer.
Haslinghuis LM; Krenning EP; De Herder WW; Reijs AE; Kwekkeboom DJ
J Endocrinol Invest; 2001 Jun; 24(6):415-22. PubMed ID: 11434665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
